onkommon.com
For researchers, funders & industry
Indian oncology runs on other people's evidence.
Twelve computational programmes closing that gap. Wet-lab free, funded from outside the clinic's margin, and built on a cohort nobody else can reproduce.
The asset nobody can buy. An Indian cohort with matched molecular, treatment, outcome and cost data, collected under consent, with ethics oversight.
The gap we exist to close
Indian cancer medicine runs on other people's evidence
Variant databases built on European ancestry. Cost-effectiveness thresholds from health systems that do not resemble ours. Screening designs assuming a workforce we do not have. Prediction models assuming complete data we rarely hold.
Each of those is a research question with a clinical consequence, and each is one that a well-funded group elsewhere has less reason to ask. That is the whole basis of this wing.
A competitor can rent a sequencer in a week and hire an oncologist in a month. Nobody can reproduce a five-year Indian cohort with matched molecular, treatment, outcome and cost data, collected under consent with ethics oversight. Every consented patient seen here adds to it.
How the wing is governed
Computational first
Our capital is compute, data, code and clinical access, none of which needs capital expenditure. Bench work goes to a collaborator who owns that capability.
Funded separately from care
It does not draw on patient revenue. Every scientific seat must be paid for by sanctioned funding.
Consent and ethics first
Research use needs a separate, independently withdrawable consent and ethics approval. Refusing it changes nothing about your care.
The cancers India actually has
Oral, head-and-neck, cervical, gallbladder and gastric disease carry a burden here that global datasets barely represent.
Why the wing is separately funded
It competes for grants, tenders and industry programmes, and does not draw on patient revenue. Every scientific seat is paid for by sanctioned funding.
That single rule is what stops research becoming the line item cut in the first difficult quarter.
The programmes
Open any one to see the question, the method and our contribution
Indian Cancer Variant Atlas & Population Genomics
Which variants seen in Indian patients are actually pathogenic?
Flagship Read the programmeDigital Twins & Treatment Response Prediction
Can we predict, before treatment starts, who will progress early?
Coming soon Read the programmeComputational Pathology & Spatial AI
Can a scanned slide predict who needs expensive sequencing first?
Coming soon Read the programmeRadiomics & Imaging AI
What do scans carry that human reading does not extract?
Coming soon Read the programmeComputational Immuno-Oncology
Beyond TMB and MSI, what actually predicts benefit in Indian patients?
Coming soon Read the programmeSingle-Cell & Tumour Ecosystem Modelling
Which cell populations drive resistance, and can we see them coming?
Coming soon Read the programmeLiquid Biopsy & Residual Disease Analytics
What monitoring interval actually changes management?
Coming soon Read the programmeAI-Guided Drug Repurposing & Combination Design
Which approved drugs could work against India-priority cancers?
Coming soon Read the programmeReal-World Evidence & Outcomes Science
What actually happens to Indian cancer patients?
Read the programmeHealth Economics & Access Modelling
At what price does molecular testing stop costing money and start saving it?
Read the programmeDecision Science & Tumour Board Quality
What actually makes a cancer treatment decision good?
Read the programmeCancer Risk Prediction & Screening Programme Design
Who should be screened, at what age, and how often?
Coming soon Read the programmeConsent, ethics and data
How patient data is, and is not, used
- Research consent is separate one of five distinct consents, taken independently, withdrawable on its own at any time.
- Refusing it changes nothing about your care. Not your appointment, not your board listing, not your plan.
- No research use without ethics approval, and a written data-use agreement for every collaboration.
- De-identification is documented, not assumed.
- We do not sell patient data. Industry funds defined research work under protocol at fair market value, never access to identifiable records, and never anything linked to prescribing.
Collaboration
What we are looking for
The wing is deliberately partnership-shaped. We hold clinical access, structured outcome data and computational capability. We do not hold a laboratory, and we say so.
- Academic collaborators for assay access, slide access and doctoral projects
- Public funders and tender programmes, particularly for screening design and health economics
- Industry research programmes real-world evidence, outcome and pharmacovigilance studies under protocol at fair market value
- Trial sponsors, where we act as a site and scientific partner
- Partner hospitals willing to contribute structured outcome data, which turns a single-city series into a multi-centre cohort
Manufacturer money linked in any way to prescribing. It is prohibited, and it would destroy the neutrality the whole institution rests on. Industry funding here buys defined research work, under protocol, publishable, or it does not happen.
Deliberately empty
Publications, funding and results
Nothing appears in this section until it exists in writing, no paper in preparation, no grant under review, no result not yet published. We would rather look early than look impressive.
Publications
Full citation, DOI and open-access link. Preprints labelled as preprints.
Funding & sanctions
Funder named, sanction reference, and the programme supported.
Ethics committee
Constitution, membership, meeting frequency and submission route, published once constituted.
Open trials
Registry number, sponsor, phase and eligibility in patient language. No number, no listing.